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Certain  aspects  of  the  relationship  of  Group A  streptococcal infection to 
rheumatic fever and rheumatic heart disease suggest that the pathogenesis of 
these nonpurulent complications are of an immunological nature. The proposi- 
tion that the rheumatic individual is a hyperimmune responder has given way 
recently to  the  concept of  an  "autoimmune" process initiated  by  Group A 
streptococcal infection. This concept is supported by finding antigens common 
to both the Group A streptococcus and heart tissues as well as cross-reacting 
antibodies in  the sera of patients with rheumatic fever and rheumatic heart 
disease (1, 2). Recently, Goldstein et al. demonstrated a specific immunological 
relationship between the Group A polysaccharide and structural glycoproteins 
in human and bovine heart valves (3).  Several authors had previously shown 
the  occurrence of circulating antibodies  to  the  streptococcal Group A  poly- 
saccharide in the sera of patients following streptococcal infections and their 
sequelae  (4-8).  Furthermore, Karakawa  et al.  demonstrated  the presence in 
human sera of antibodies to the A polysaccharide as well as to a  degradation 
product of this antigen, the A-variant polysaccharide (8). 
The purpose of this study was to determine the antibody levels to both the A 
and A-variant antigens as well as the frequency of the occurrence of these anti- 
bodies in  normal  individuals  and  in  patients  with  nonpurulent  sequelae  of 
Group A  streptococcal infection. Antibody levels to these two antigens were 
assayed in patients with the nonpurulent sequelae as a possible means of deter- 
mining whether an abnormality in the in vivo processing of the Group A poly- 
saccharide existed in some of the patients. Because of the reported cross-reac- 
tivity of antibody to the A  polysaccharide with heart valve glycoprotein, the 
streptococcal Group A polysaccharide antibody levels were determined in sera 
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of patients with rheumatic valvulitis. The following report presents our findings 
on  the  distribution  of antibodies  to  the A  and  A-variant  antigens  in  patients 
with rheumatic and nonrheumatic  sequelae of Group  A  streptococcal infection 
together with data showing prolonged persistence of the antibody reacting with 
the Group A  polysaccharide in patients with rheumatic valvulitis. 
Materials and Methods 
Sera.--The majority of patients studied with acute rheumatic fever, Sydenham's chorea, 
and acute glomerulonephritis had been previously evaluated for the antibody response to the 
streptococcal extracellular antigens  (9,  10).  The diagnostic criteria for these diseases were 
previously defined (9,  10). Follow-up sera for antibody studies during the convalescent and 
inactive stages of these diseases were obtained on these patients as well as additional patients 
whose initial manifestation fulfilled the required diagnostic criteria. Control sera were obtained 
from individuals who had no clinical evidence of streptococcal infections or their sequelae or a 
history of an undiagnosed pharyngitis in the 2 months prior to bleeding. The controls were 
age matched with the patients in each  category studied. 
Sera were processed with sterile precautions and stored at -- 10°C  until used. 
Strains o/Streptocoeci.--The Group A  streptococcal strain,  B-140,  and  Group A-variant 
strain 6108, were kindly supplied by Dr. Rebecca Lancefield. 
Tlyperimmune Rabbit Antisera.--A and A-variant rabbit antisera were kindly supplied by 
Dr. Rebecca Lancefield. 
CherM~al Analyses.--Rhamnose determinations were performed using the method of Dische 
and Shettles (11). Glucosamines were determined by the method of Rondle and Morgan (12) 
after hydrolysis of the carbohydrate in 2 N HC1 for 4 hr at 100°C. 
A  and A-Variant Antibody  Determinations.--The  antibody levels were determined by a 
modification of the radioimmune precipitation technique described by Halpern and Goldstein 
(6). 
Preparation of 14C-labeled Group A  and A-variant carbohydrate antigens: Group A strepto- 
cocci were grown in Todd-Hewitt broth to which x4C-labeled acetate had been added to a final 
concentration of 2.5/zc of nC-acetate/1 ml of broth. Group A-variant organisms were labeled 
with 1*C-glucose  using 0.6 #c/1 ml of broth. Mter overnight incubation, the cells were collected 
by centrifugation and washed.  Cell walls were prepared by Mickle disintegration  and  dif- 
ferential centrifugation according to the method  of Salton and  Home  (13).  Group-specific 
carbohydrates  were extracted from lyophilized cell walls by the hot formamide method  of 
Fuller as modified by Heymann et al. (14). The solution of the formamide-extracted labeled 
carbohydrate was dialyzed for 48 hr against two changes of distilled water. Because of the low 
yield expected from the small amount of cell walls extracted, the labeled carbohydrate was not 
lyophilized. The dialyzed solution was used as a stock from which appropriate dilutions were 
made for the tests. In order to determine the concentration of carbohydrate antigen in solu- 
tion, 0.1 ml aliquots were assayed for rhamnose and glucosamine content. The A carbohydrate 
solution was  found to contain 600/~g rhamnose/ml and  280/zg  glucosamine/ml while the 
A-variant preparation contained 210 #g rhamonse/ml and 10 tzg glucosamine/ml. The relative 
percentages of rhamnose and glucosamine in these preparations are similar to those obtained 
by Kranse and McCarty (15) for their preparation of formamide-extracted A and A-variunt 
carbohydrates. 
Based on these results, it was considered that the A carbohydrate solution contained the 
equivalent of 1 nag of antigen/ml and the A-varimat solution contained 0.233 mg of antigen/ml. 
The validity of the correlation of these antigen concentrations with the rhamnose-glucosamine 
ratios obtained on the solutions was verified by using the labeled A and A-variant carbohydrate BURTON  A. DUDDING  AND  ELlA M.  AY01YB  108 3 
preparations in a  quantitative precipitation technique with specific rabbit A and A-vaxiant 
antisera. The curves obtained in these tests were similar to those obtained using corresponding 
amounts of unlabeled A and A-variant antigens with known rhamnose content. 
Radioimmune precipitation technique: 0.2 ml of patient sera and the appropriate amount of 
14C-labeled carbohydrate antigen (v/de infra)  in 0.8 ml of normal saline were mixed in thick- 
walled glass tubes, incubated for 60-90 rain at 37°C and then allowed to stand for 24 hr at 4°C 
with occasional shaking. An equal amount  (1 ml) of saturated ammonium sulfate  solution 
was then added with shaking to each sample. After allowing the samples to stand for 1 hr in 
the cold, the tubes were centrifuged at 4°C at 6000 g for 15 rain. The supernatant was removed 
and the precipitate was solubilized in I ml of NCS reagent,  x 5 ml of scintillation fluid  2 added 
to the clear solution, the contents were mixed and transferred to a counting vial. The tube was 
rinsed with an additional 5 ml of scintillation fluid which was combined with the solution in 
the counting vial. Samples were counted at 4°C for 20 min in a Packard Tri-Caxb liquid scin- 
tillation counter. 
Preliminary experiments using longer periods of incubation and precipitation at 4°C  or 
additional washings did not significantly alter the amount of radioactivity obtained for the 
samples. 
To determine the total radioactivity (100%) of the antigen added to each serum, an equiva- 
lent amount of the labeled carbohydrate contained in 0.1 ml of distilled water was added to a 
vial cont~n~ng precipitated protein from 0.2 ml of normal serum solubilized in NCS reagent 
followed by the addition of 10 ml of scintillation fluid. 
The antibody level in the test serum was calculated by dividing the counts per minute in 
the test serum by the cpm obtained for the total activity (100%) of labeled antigen added. 
Degermination of antigen-antibody ratio: According to Farr  (16), optimal antibody deter- 
minations axe obtained in this system in slight antigen excess or when approximately 80% 
of the antigen is precipitated. Because Halpern and Goldstein (6) had shown that the highest 
antibody levels were present in patients with acute rheumatic fever, different concentrations 
of the 14C-labeled Group A carbohydrate antigen were tested with varying amounts of sera 
from several patients with acute rheumatic fever in order to establish optimal amounts of 
antigen and antibody to be used in the determinations. The results showed that in most 
patients in this group approximately 80% of the radioactivity was precipitated when 1/zg 
of the labeled carbohydrate and 0.2 ml of serum were used. These amounts are approximately 
proportional to the amounts of antigen and sera used by Halperu and Goldstein (1.5-2.0 #g 
of antigen]0.5 ml sera) (6). 
Initial tests with the A-variant antigen revealed that 0.2 ml of serum from patients with 
acute rheumatic fever precipitated approximately 40-50% of the 1 #g of labeled A-variant 
antigen. Although these values were in the antigen excess range, the same amount of total 
carbohydrate antigen (1/zg) was used for both the A and A-variant antibody determinations 
in order to measure the relative magnitude of the response to these two antigens. 
Anti,  streptolysin 0  (ASO)  and Anti-Desoxyribonuclease (Anti-DNase  B) Determinations.-- 
ASO and anti-DNase B  titers were measured by either the macro method or micro methods 
previously described (9,  17, 18). 
RESULTS 
A  and A-Variant  Antibodies  in Acute Rheumatic  Fever and Acute Glomerulo- 
nephritis.--A  and A-variant antibody levels as well as ASO and anti-DNase  B 
a Quaxternary ammonium compound, Nuclear-Chicago Corp. Des Plalnes, IlL 
4 g PPO, 300 ml absolute ethanol, 700 ml toluene. 1084  STREPTOCOCCAL GROUP  A  ANTIBODY 
titers were determined on sera from 48 patients with acute rheumatic fever and 
33 patients with acute poststreptococcal glomerulonephritis. Sera were obtained 
within 2 months after the onset of symptoms in each disease. 32 of the patients 
with rheumatic fever had experienced an initial attack while 16 patients had a 
recurrent attack.  All  patients  with  rheumatic fever had  clinical evidence of 
carditis during the acute stages of the illness. Antibody determinations obtained 
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FIG. 1. Distribution of streptococcal Group A carbohydrate antibody levels (fraction pre- 
cipitated) in acute glomerulonephritis, acute rheumatic fever, and in age-matched normal con- 
trols. Open circles,  used for controls only, indicate individuals with elevated anti-streptolysin 
O (ASO) and/or anti-deoxyribonuclease (anti-DNase B) antibody titers. The geometric means 
of the antibody levels for each category are shown at the bottom of the figure,  together with 
the P  value for the statistical significance  of the difference between the means. 
for both groups of patients were compared with those obtained from a similar 
number  of  age-matched normal  controls.  Fig.  1  shows  the  distribution  and 
means of the A antibody levels, expressed as fractions of radioactivity precipi- 
tated, in sera of patients with acute rheumatic fever and acute glomerulonephri- 
tis, and of age-matched normal controls. Although the A antibody levels of pa- 
tients with acute rheumatic fever appear slightly higher than those of patients 
with acute nephritis, the means of these levels were not significantly different in 
these two groups of patients. However, the mean A antibody levels for both the 
rheumatic fever and nephritis groups differed significantly from those obtained BURTON  A.  DUDDING  AND  ELlA  M.  A¥OUB  1085 
on control groups (P =  <  0.001). The occurrence of high A  antibody levels in 
some normal  controls in  the  absence  of elevated  ASO and/or  anti-DNase  B 
titers is probably due to a relatively slower decline of the A carbohydrate anti- 
body than either the ASO or anti-DNase B antibodies. 
Fig. 2 shows the distribution of A-variant antibody levels in sera from these 
same patients  and  controls.  The A-variant  antibody levels  were  consistently 
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ACUTE  ACUTE  CONTROLS 
CONTROLS  GLOMERULONEPHRITIS  RHEUMATIC  FEVER 
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Fro. 2. Distribution  and means of Group A-variant carbohydrate  antibody levels (fraction 
precipitated)  in acute glomerulonephritis, acute rheumatic  fever, and controls. Open circles, 
used for controls only, indicate individuals with elevated anti-streptolysin  O (ASO) and/or 
desoxyribonuclease (anti-DNase  B)  antibody titers.  The geometric means of the antibody 
levels for each category are shown at the bottom of the figure, together with the P value for 
the statistical  significance of the difference between the means. 
lower than those for the A antibody but the mean ratio of A-variant to A levels 
was similar for patients with acute rheumatic fever (0.49)  and acute nephritis 
(0.48). There was again no significant difference in the mean A-variant antibody 
level among patients with rheumatic fever and acute nephritis,  whereas  mean 
A-variant levels for both diseases were significantly greater than control levels. 
Table I summarizes the results of the mean A and A-variant levels as well as the 
geometric means  of the  ASO and  anti-DNase  B  titers  for patients  and  their 
controls. 
In the study of Karakawa et al.  (8), a positive correlation was found between 
the ASO titers and both the indirect anti-Group A  and the direct anti-Group 1086  STREPTOCOCCAL  GROUP  A  ANTIBODY 
A-variant agglutination titers.  An  evaluation was  carried  out  to  determine 
whether a similar correlation would be obtained for the ASO or anti-DNase B 
titers and the Group A antibody levels assayed by the radiojmmune precipitin 
technique.  Fig. 3 illustrates the correlation of the A antibody levels with ASO 
and anti-DNase B titers in patients with acute rheumatic fever and acute ne- 
phritis, and in control patients. The values for the degree of correlation of the A 
TABLE  I 
Mean Antibody Determinations in Acute Rheumatic Fever and Acute 
Glomerulonephritis and Controls 
Antibody  test 
A antibody 
A-variant antibody 
Ratio, A-variant to A antibody 
Geometric mean, ASO 
Geometric mean, anti-DNase B 
Acute rheumatic fever 
Patients  Controls 
0.77  0.41 
0.39  0.23 
0.49  0.56 
400  120 
4OO  80 
Acute glomerulonephrifies 
Patients  Controls 
0.70  0.40 
0.33  0.22 
0.48  0..55 
500  100 
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FIo. 3. Correlation of Group A carbohydrate antibody levels with the log of ASO and anti- 
DNase B antibody titers for 48 patients with acute glomemloncphritis, 33 patients with acute 
rheumatic fever, and 63 age-matched controls. BURTON  A.  DUDDING  AND  ELIA  ]~.  AYOUB  1087 
antibody with ASO and anti-DNase B antibodies were r 4- 0.620 and r 4- 0.590 
respectively. In each instance, a P  value of <  0.001 was obtained indicating a 
correlation of high significance. 
A and A-Variant Antibody in Chronic Inactive Rheumatic Heart Disease.--The 
possibility of a prolonged persistence of the A antibody suggested by the find- 
ings in some patients of elevated A antibody levels with normal ASO and anti- 
"A" Antibody  "A-Variant" Antibody 
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FIG. 4. Distribution and means of Group A and A-variant carbohydrate  antibody levels 
(fraction precipitated) in patients with chronic inactive rheumatic  heart disease  on penicillin 
prophylaxis  and in  normal controls. 
DNase B fiters was investigated by determining A and A-variant antibody levels 
on sera from 45 patients with inactive rheumatic heart disease, obtained 1-25 yr 
after the last acute episode. Although the mean A-variant level was similar to 
the control value, the mean A  antibody level was 0.58,  a  value intermediate 
between that obtained for patients with acute rheumatic fever (0.77)  and their 
controls (0.40). In order to exclude the possibility that  recent streptococcal in- 
fections contributed to this elevated A antibody level, 30 patients who had been 
on adequate secondary prophylaxis, and whose date of most recent active dis- 
ease could be established, were selected for further analysis. 
A and A-variant antibody determinations as well as ASO and anti-DNase B 1088  STREPTOCOCCAL  GROUP A  ANTIBODY 
titers performed on sera from these 30 patients with chronic inactive rheumatic 
heart disease were compared with those obtained from 30 age-matched controls. 
The mean A antibody level (0.64) for patients with chronic inactive rheumatic 
heart  disease  was  significantly higher than  the mean  antibody level for the 
control group (0.43),  whereas there was no significant difference in mean A- 
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Fro.  5.  Distribution of Group A  carbohydrate antibody levels (fraction precipitated) in 
patients with chronic inactive rheumatic heart disease on penicillin prophylaxis shown in re- 
[arian  to the number of years elapsed after the patient's last acute rheumatic attack. The 
geometric means for titers obtained on patients seen within 5 yr after last active attack are 
compared with the mean of the titers obtained on patients tested 6-25 yr after their last ac- 
tive episode. The difference in the means shows no statistical significance  (P value >  0.70). 
variant  antibody levels (0.29,  0.23)  (Fig.  4).  The geometric mean  ASO  and 
anti-DNase B titers for the patients with chronic rheumatic heart disease were 
100 and 83,  respectively; values which were identical with those for the same 
antibodies  obtained  in  the  control group.  The finding  of  similar  A-variant 
levels, ASO and anti-DNase B  titers in these patients with chronic rheumatic 
disease who had been on secondary prophylaxis, makes unlikely the possibility 
that the elevated A antibody levels were the result of intercurrent streptococcal 
infections. BURTON  A. DUDDING  AND  ELIA M. AYOUB  1089 
An estimate of the duration of the persistence of the Group A antibody in 
these 30 patients was obtained by comparing each patient's antibody level with 
the number of years that had elapsed since the patient's last rheumatic activity 
(Fig. 5). No significant difference was observed when the mean A antibody level 
(0.65)  obtained for 13 patients who had evidence of active disease within the 
past 5 yr was compared to the mean level (0.63) for 17 patients who had active 
disease 6-25 yr prior to the date the serum specimen examined was obtained. 
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,rFIG. 6. Distribution of Group A carbohydrate antibody levels (fraction precipitated) in 45 
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within 1 yr prior to the time the blood specimen was obtained. 
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The relation of age to A antibody levels in patients with inactive rheumatic 
valvulitis was examined and the results are shown in Fig. 6. Group A antibody 
levels on all 45 patients with chronic inactive rheumatic heart disease were in- 
cluded in this analysis and were correlated with the age of each patient at the 
time the blood specimen was obtained. The results suggest that the mean A 
antibody levels in patients with chronic inactive rheumatic heart disease are 
elevated in the 10-40 yr age range but decline to normal levels after 50 yr of age. 
A  and A-Variant Antibody Levels in Patients with Nonpurulent Sequelae of 
Streptococcal Infection,  with or without  Valvular  Disease.--The finding of ele- 
vated A antibody levels in patients with chronic inactive rheumatic heart dis- 
ease which could not be explained by a recent streptococcal infection suggested 1090  STREPTOCOCCAL  GROUP  A  ANTIBODY 
the possibility that persistence of these antibodies might be a specific immuno- 
logic phenomenon found only in patients with rheumatic carditis and residual 
valvular disease.  This  possibility was  studied by  comparing  the  pattern  of 
decline in the A, A-variant, ASO, and anti-DNase B antibodies in three groups 
of patients with various sequelae of Group A streptococcal infections: (a) post- 
streptococcal glomerulonephritis, (b)  Sydenham's chorea (without evidence of 
carditis),  and  (c)  acute rheumatic fever with  carditis and  residual valvular 
disease. 
The sera obtained on these patients were examined at three periods following 
the suspected precipitating streptococcal infection: up to 4 months, 5-12 months 
and 1-5 yr. All available paired sera were used and, in the absence of paired sera, 
single sera obtained from patients seen during the time interval being studied 
were used. A total of 21 sera were available for this evaluation from 12 patients 
with glomerulonephritis (9 single sera, 12 paired) ; 21 sera from 15 patients with 
rheumatic valvulitis (15 single sera, 6 paired sera); 18 sera from 16 patients with 
Sydenham's chorea who exhibited no rheumatic heart disease (14 single sera, 4 
paired sera). Thus, seven sera for each patient category were available for study 
at each of the three time intervals except for the period of 1-5 yr in patients with 
Sydenham's chorea, where only four sera were available. 
In patients with no history of an antecedent streptococcal infection, the inter- 
val from the infection to the date of the bleeding was based on the expected 
mean period of latency for the various sequelae, i.e.,  10 days for acute glo- 
merulonephritis, 20 days for acute rheumatic fever (19),  and 3-4 months for 
Sydenham's chorea (20). It should be pointed out that because the initial period 
extended up to 4 months after the onset of the clinical manifestation, variations 
of about 2 wk in the latency period for rheumatic fever and glomerulonephritis 
were not considered a factor that would affect significantly these comparative 
evaluations. For similar reasons, and because of the longer latency period, all 
patients with Sydenham's chorea from whom sera were obtained within 1 month 
following the onset of clinical symptoms were arbitrarily included in the initial 
period 
Mean A  antibody levels during these three intervals are shown in Fig.  7. 
During the initial period of 4 months, the mean A antibody levels were elevated 
to a similar level in patients with acute nephritis, chorea, and rheumatic cardi- 
tis. During the following 8 months, the mean A antibody level in rheumatic 
patients  with  valvular  disease  showed a  minimal  decline  (0.87-0.83)  while 
patients  without  valvular  disease  (Sydenham's  chorea)  and  acute  neph- 
ritis exhibited a  marked decrease in their mean A antibody levels (0.82-0.53 
and 0.82-0.48).  The mean A antibody decreased further during the following 4 
yr period in these latter two groups of patients while the rheumatic patients 
with heart disease showed only a minimal decline (0.83-0.80). 
A relationship between the persistence of the A antibody and the presence of BURTON  A.  DUDDING AND  F.LIA M.  AYOUB  1091 
valvular heart disease in rheumatic patients was again suggested by the results 
of antibody determinations performed on four additional sera obtained at 1-5 yr 
following the onset of disease from patients with Sydenham's chorea who had 
evidence of valvular heart disease. The mean A antibody level in four such pa- 
tients' sera was 0.72, a value which more closely approaches the mean of 0.80 for 
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FIG. 7. Mean Group A carbohydrate antibody levels in patients with rheumatic fever with 
valvular heart disease,  poststreptococcal glomerulonephritls, and Sydenlmm's chorea deter- 
mined at various time intervals after the onset of the acute episode. All of the patients with 
rheumatic valvulitis had been placed on penicillin prophylaxis after the acute attack. 
rheumatic patients with valvulitis in the follow-up period than the mean of 0.38 
obtained in the four patients with "pure" chorea. 
The results of all antibody determinations (A,  A-variant,  ASO, and anti- 
DNase B) on these sera from rheumatic patients with valvulitis and patients 
with acute glomerulonephritis are shown in Figs. 8 and 9. During convalescence 
and follow-up, the means of the ASO and anti-DNase B titers decline in both 
groups of patients, while only in those rheumatic patients with valvulitis does 
the mean A antibody remain elevated. 
In patients with rheumatic valvulitis,  the decline in the A-variant antibody 
appears  to parallel the decline of the A antibody. However,  the pattern of de- 
dine for the A-variant antibody in these patterns is similar to that seen in pa- 
tients with glomerulonephritis  and Sydenham's chorea.  Statistical analysis of 1092  STREPTOCOCCAL GROUP A  ANTIBODY 
1.00 
0.90 
0.80 
"~  0.70 
"~ ~  0.60 
o5o 
.~ 
~  0.40 
"  0.30 
0.20 
0.10 
0.00 
3.0 
Meon 
%  ~'~nh~ody 
e~  e-  --e 
Mean 
o?  ~'~'~,  ,4nh'-O/VAse  B  %%. 
Mean  %,  ~.\  Tiler 
ASO Tiler  "-,  ~%,~/ 
Anlibddy 
I 
I  ] 
I  I 
I  I 
4 me  12me  2yr  3yr 
Interval  After Acute Disease 
FTO. 8. Mean Group A and A-variant antibody levels and mean log ASO and anti-DNase B 
antibody tilers in patients with rheumatic fever with valvulitis determined at various time 
intervals after the onset of the last acute episode. 
2.8 
2.6 
2.4 
2.2 
2.0 
1.8 
1.6 
I 
4yr  5yr 
I- 
o 
._ 
o~ 
O 
--J 
1.00 
0.90 
0.80 
0.70 
0.60  g~ 
A" ~  o.5o 
._g ~- 
04o 
b.. 
0.:50 
0.20 
0.10~- 
0.001 
:..~  I-  Mean  ,>,.,.",~  ~"  ~nlfbody 
Mean  ~'., 
*%  %.  ...,0 
Mean  ~'~  """  "-o.._... 
'~ - Variant" 
Antibody  /  ",  ""  "'"-  """ 
Mean  " 
Tiler 
I  j,,,__ l  I 
4mo  12mo  2yr  5yr 
I 
4yr 
5.0 
2.8 
2,6 
2.4 
2.2 
-  2.0 
t 
1.8 
1.6 
5yr 
Interval  After  Acute  Disease 
Fzo. 9. Mean Group A and A-variant antibody levels and mean log ASO and anti-DNase B 
antibody tilers in patients with poststreptococcal giomerulonephritis determined at various 
time intervals after the onset of the acute episode. 
i: 
o 
c 
_1 BURTON  A.  DUDDING  AND  ELIA  1~I. AYOUB  1093 
the mean A-variant antibody levels for the three time intervals studied in the 
three patient groups revealed differences that were either of borderline or no 
significant differences (Fig. 10). 
DISCUSSION 
The occurrence of antibodies to streptococcal Group A carbohydrate in man 
has been described by several authors (4-8). Halpern and Goldstein first utilized 
the radioimmune precipitin technique to quantitate the levels of this antibody in 
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FIo. 10. Mean Group A-variant antibody levels in patients  with rheumatic  fever with valvu- 
lar heart disease,  poststreptococca! g|omemlonephritis,  and Sydenbam's chorea determined at 
various time intervals after the onset of the last acute episode. 
human sera (6). Their study showed the presence of higher levels of this antibody 
in patients with rheumatic fever than in a  group of controls. Using a  tanned 
red cell  hemagglutination technique,  Schmidt  and Moore  (7)  demonstrated 
low but measurable A antibody titers in most normal children and adults, and 
high titers in patients with streptococcal infections and their complications. 
Antibodies to both A and A-variant carbohydrates were detected in human sera 
by Karakawa et al. (8) using direct and indirect agglutination techniques with 
cell walls. The A and A-variant antibody titers measured by this method showed 
correlation with the ASO titers suggesting that the occurrence of the carbo- 
hydrate antibodies was another feature of the host response to streptococcal 
infection. Karakawa et al. attributed the occurrence of the A-variant antibodies 
in human sera (8) and in experimental animals (21) to an in vivo degradation of 1094  STREPTOCOCCAL GROIYP A  ANTIBODY 
the group A antigen. This was supported by the evidence obtained by Ayoub 
and McCarty (22) for a fl-N-acetylglucosaminidase in phagocytic cells that can 
degrade  the  group A  carbohydrate to  the A-variant carbohydrate,  and  the 
findings of Schwab and Ohanian (23) of an in vivo degradation of the A  antigen 
in experimental animals. 
The radioimmune precipitation technique, unlike other methods for antibody 
determinations, is a  semiquantitative method for assaying antibody. For this 
reason, the word level was substituted for titer in our reporting of the  results. 
Nevertheless, the correlation (r values)  (Fig. 3)  for the ASO antibody  titers 
versus the A antibody levels using this method was similar to that reported by 
Karakawa et al. (8) for the A antibody titers assayed by the hem_agglutination 
technique. Given the above limitation, the results obtained in this study indi- 
cate the usefulness of this technique in comparative evaluations as shown by the 
significant differences obtained for the antibody levels in the patient and control 
sera. As pointed out by Halpern and Goldstein (6), the optimal amount of anti- 
gen to be used in this system is that amount which will yield antibody levels of 
0.80, which corresponds to a  slight antigen excess.  In this study, the mean A 
antibody level in patients with acute rheumatic fever was 0.77, indicating that 
optimum proportions of antigen to antibody were used. However, the mean A- 
variant antibody level for patients with acute rheumatic fever was 0.38 reflect- 
ing an excess of antigen in our assay for this antibody. The use of this amount of 
antigen was dictated by the limited amount of serum available on the patients 
and the low specific radioactivity of the labeled A-variant carbohydrate antigen. 
Our studies on the A and A-variant antibody were carried out to determine 
whether an abnormality in the processing of the A to A-variant carbohydrate 
could be detected in patients with rheumatic fever. Such an abnormality could 
be manifested by finding different levels and ratios of the antibodies to carbo- 
hydrate antigens between patients with rheumatic fever and patients with non- 
rheumatic complications of streptococcal infection. It is felt that the A-variant 
antibody levels reported in this study do not represent the maximal A-variant 
levels that can be obtained in the sera of the various populations studied. How- 
ever the levels obtained were only used to determine the ratio of the A-variant 
to A antibody levels which could reflect the different capacities of patients with 
various nonsuppurative complications of Group A streptococcal disease to de- 
grade the A antigen in vivo. The similarity of the mean ratios of A-variant to A 
antibody levels in the patients with acute rheumatic fever and acute glomerulo- 
nephritis (Table I) would suggest that degradation of the streptococcal Group A 
carbohydrate antigen within the host occurs to the same extent in both diseases. 
Prolonged persistence of the A antibody was initially suspected when it was 
noted that several patients and normal controls had elevated levels of this anti- 
body with normal ASO and anti-DNase B titers. The persistence of the A anti- 
body levels was confirmed by finding elevated A antibody levels in patients with BURTON  A. DUDDING AND  ELIA M.  AYOUB  1095 
chronic inactive rheumatic heart disease when compared  to an age-matched 
control group. That the elevation  of the A antibody in these patients was a 
result of recent streptococcal infection was made improbable by demonstrating 
that ASO and anti-DNase B titers as well as A-variant antibody levels in these 
sera were in the normal range. In some patients' sera high levels of A antibody 
were found 20-25 yr after their last episode of rheumatic activity. Elevated A 
antibody  levels were found in all ages  of patients with chronic inactive rheumatic 
heart disease with the exception of those individuals past age 50. In these older 
individuals the mean A antibody level was similar to the mean obtained in con- 
trol patients' sera. 
Because antibodies  to the type-specific streptococcal  M  antigen have been 
shown to persist for similar periods of time (24) in patients with and without the 
nonpurulent complications of streptococcal infection, the persistence  of the A 
antibody in patients with poststreptococcal  glomerulonephritis was  examined. 
The results revealed a marked difference in the pattern of the decline of the A 
antibody levels between these patients and those with rheumatic fever, although 
the decline of antibody titers to the other streptococcal antigens were similar in 
both patient categories. This finding was interesting in view of the cross-reac- 
tivity between the Group A polysaccharide antigen and structural glycoprotein 
in human heart valves reported by Goldstein et al. (3) and raised the possibility 
that prolonged persistence of the A antibody may be specifically related to the 
occurrence of valvulitis in rheumatic disease. The specificity of this relationship 
was further supported  by the  data  obtained  on  patients with  Sydenham's 
chorea. Patients with pure  Sydenham's chorea show a pattern of A antibody 
decline similar to that seen in poststreptococcal  glomerulonephritis  while pa- 
tients with chorea associated with valvular heart disease manifest the pattern of 
persistence of this antibody seen in patients with rheumatic valvulitis. 
As with previous  reports  of the presence of antibodies  common to various 
components of the Group A streptococcal cell and heart tissues (1-3), the simple 
occurrence of an antibody that cross-reacts with the Group A polysaccharide 
and the glycoportein of heart valves cannot be construed to be of pathogenetic 
significance. This antibody appears  in sera of patients following streptococcal 
infection and is  also  present  in  the  acute form of the  various nonpurulent 
complications of this infection. In fact, the highest titers for this antibody ob- 
tained in the study reported by Schmidt and Moore (7)  occurred in patients 
with streptococcal sepsis. The presence of elevated levels of this antibody at one 
point in time can only be interpreted as reflecting an antibody response to this 
antigen,  similar to the response for the other streptococcal  antigens. However, 
the singular phenomenon observed in this study regarding the persistence of the 
Group A  carbohydrate antibody compared  to  antibodies directed  to  other 
streptococcal antigens and only in the presence of chronic valvular damage, is of 
significance  in suggesting a pathogenetic relationship. 1096  STREPTOCOCCAL GROUP A  ANTIBODY 
That genetic differences could be associated with specific manifestations and/ 
or complications of rheumatic fever is suggested by two recent reports.  In a 
study of haptoglobin phenotypes and levels of rheumatic and nonrheumatic 
individuals, Murray et al.  (25) showed an increased frequency of Hp 0  type 
haptoglobin in rheumatics with heart disease, and an increased frequency of the 
lip  1-1  type in patients with pure Sydenham's chorea. The lip 0 and hypo- 
haptoglobinemic subjects were confined to rheumatics with cardiac sequelae. 
Recent studies by Spagnuolo and Taranta (26) indicate that siblings with rheu- 
matic fever tend to have the same manifestations and sequelae.  Our present 
findings offer evidence for an immunological peculiarity that sugests a specific 
relationship with valvular disease.  This immunological phenomenon is related 
to an antigen common to both an organism causally related to the disease,  the 
Group A streptococcus, and to the tissue which is the site of injury in the disease, 
the heart valve. The mechanism that accounts for this phenomenon is unknown. 
The specificity of this finding has as yet to be  further confirmed by studying 
patients with valvular heart disease of nonrheumatic  etiology. Whether the 
persistence of this antibody is the result of the valvulifis or is actively involved 
in the pathogenesis of the disease should be clarified by further studies. 
S~RY 
Antibody levels  to streptococcal  Group A and A-variant carbohydrates were 
determined using  a  radioactive  immune precipitation  technique  on  patients  with 
rheumatic fever,  with and without valvular disease,  on patients  with post- 
streptococcal  acute glomcrulonephritis,  and on age-matched controls.  During 
the acute phase of the above illness,  the means of the antibody levels  to both 
carbohydrate antigens  were equally  elevated  and were significantly  higher  than 
the normal controls.  When  Group A  antibody levels  were determined on sera 
obtained at intervals  of 5-12 months and 1-5 yr after  the acute illness,  it  was 
found that the antibody levels  declined  within the normal range at the 5-12 
month interval  in patients  with glomcrulonephritis  as well  as in patients  with 
rheumatic fever  in  whom no  valvular  involvement had complicated the  disease, 
i.e.,  patients  with  pure  Sydcnham's chorea.  However, in  patients  with  rheumatic 
va~vulitis,  who had been on pcniciUin  prophylaxis after  the last  acute episode, 
the A  antibody level  showed little  decline  from the level  obtained during the 
acute  illness.  The elevated  antibody level  in  patients  with  rheumatic valvulitis, 
including  patients  with Sydenham's chorea  with  valvulitis,  persisted  for  periods 
of  at  least  I yr and up to 20 yr after  the  last  acute attack.  The pattern of the 
decline  of the antibody levels  to the A-variant carbohydrate  as well  as of the 
antibody titers  to  the  other  streptococcal  antigens  tested,  ASO and anti-DNase 
B, was similar  in  all  patients  studied  regardless  of  the  presence of  valvular  dis- 
ease.  These  findings  suggest  that  prolonged persistence  of  the Group A  antibody 
is  a  phenomenon peculiar  to  patients  with rheumatic valvular disease.  Whether BURTON  A.  DUDDING  AND  ELIA  M.  A¥OUB  1097 
this persistence is involved in the pathogenesis or is an outcome of the valvular 
disease remains to be determined. 
The authors would like to acknowledge the technical assistance of Carol Dahl, JoAnn Nel- 
son, and Joanne Kumagai. 
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